
John Lechleiter, chairman, president and chief executive of Lilly has been elected chairman of the Pharmaceutical Research and Manufacturers of …
Celgene, the biopharma firm specialising in cancer and inflammatory diseases, has elected Richard Barker to its board of directors. Dr …
Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director. Gillen brings much …

Celgene has opened new UK headquarters in London as its haematology-based business expands. The firm says it has decided to …
Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …
Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …
NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …
Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …

